HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
zL6XKdX5YjNgkZhu